BG60766B2 - Производни на хексадеканова и хексадекадиенова киселини - Google Patents

Производни на хексадеканова и хексадекадиенова киселини Download PDF

Info

Publication number
BG60766B2
BG60766B2 BG098503A BG9850394A BG60766B2 BG 60766 B2 BG60766 B2 BG 60766B2 BG 098503 A BG098503 A BG 098503A BG 9850394 A BG9850394 A BG 9850394A BG 60766 B2 BG60766 B2 BG 60766B2
Authority
BG
Bulgaria
Prior art keywords
formula
compound
hexyl
hydroxy
formamido
Prior art date
Application number
BG098503A
Other languages
Bulgarian (bg)
English (en)
Inventor
Paul Hadvary
Erich Hochull
Ernst Kupfer
Hans Lengsfeld
Ernst Welbel
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4255488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG60766(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of BG60766B2 publication Critical patent/BG60766B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG098503A 1983-06-22 1994-02-21 Производни на хексадеканова и хексадекадиенова киселини BG60766B2 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH341583 1983-06-22

Publications (1)

Publication Number Publication Date
BG60766B2 true BG60766B2 (bg) 1996-02-29

Family

ID=4255488

Family Applications (1)

Application Number Title Priority Date Filing Date
BG098503A BG60766B2 (bg) 1983-06-22 1994-02-21 Производни на хексадеканова и хексадекадиенова киселини

Country Status (26)

Country Link
US (1) US4598089A (instruction)
EP (1) EP0129748B1 (instruction)
JP (1) JPS6013777A (instruction)
KR (1) KR920002314B1 (instruction)
AT (1) ATE30025T1 (instruction)
AU (1) AU572851B2 (instruction)
BG (1) BG60766B2 (instruction)
CA (1) CA1247547A (instruction)
DE (2) DE3466538D1 (instruction)
DK (1) DK160496C (instruction)
ES (1) ES533557A0 (instruction)
FI (1) FI78694C (instruction)
GR (1) GR82120B (instruction)
HU (1) HU193579B (instruction)
IE (1) IE57761B1 (instruction)
IL (1) IL72122A (instruction)
LU (1) LU90302I2 (instruction)
LV (1) LV5747B4 (instruction)
MC (1) MC1602A1 (instruction)
MX (1) MX9203633A (instruction)
NL (1) NL980029I2 (instruction)
NO (2) NO159941C (instruction)
NZ (1) NZ208521A (instruction)
PH (1) PH19704A (instruction)
PT (1) PT78777B (instruction)
ZA (1) ZA844558B (instruction)

Families Citing this family (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA859574B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Process for the manufacture of oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
JPH0618793Y2 (ja) * 1986-06-13 1994-05-18 パイオニア株式会社 作業台
US4806564A (en) * 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4816477A (en) * 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5484777A (en) * 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5017565A (en) * 1989-04-20 1991-05-21 Lange Iii Louis G Use of sulfated polysaccharides to inhibit pancreatic cholesterol esterase
JP2960947B2 (ja) * 1989-12-25 1999-10-12 日清製粉株式会社 脂質分解酵素阻害剤
US5376640A (en) * 1989-12-25 1994-12-27 Nisshin Flour Milling Co., Ltd. Lipolytic enzyme inhibitors
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
MY116591A (en) * 1996-04-26 2004-02-28 Hoffmann La Roche Process for the production of lipstatin and tetrahydrolipstatin
HU230834B1 (hu) * 1997-02-05 2018-07-30 F.Hoffmann-La Roche Ag Tetrahidrolipsztatin felhasználása
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US7344713B1 (en) * 1997-07-07 2008-03-18 Pimentel Julio L Decreased fat absorption with an anti-lipase antibody
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
RU2234917C2 (ru) * 1997-12-24 2004-08-27 Кнолль Акциенгезелльшафт Терапевтические средства
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
CA2340052C (en) * 1998-08-14 2007-05-29 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
DK1105122T3 (da) 1998-08-14 2005-08-08 Hoffmann La Roche Pharmaceutical compositions containing lipase inhibitors
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
US6562860B1 (en) 1998-12-23 2003-05-13 G. D. Searle & Co. Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
CZ20012341A3 (cs) 1998-12-23 2001-12-12 G. D. Searle Llc Corparate Patent Department Kombinace inhibitorů transferoního proteinu cholesterylesterů a derivátů kyseliny fibrové pro kardiovaskulární indikace
PL348508A1 (en) 1998-12-23 2002-05-20 Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
ES2200588T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinacion de inhibidores del transporte de oxido biliar ileal y de derivados de acido fibrico para indicaciones cardiovasculares.
ATE242008T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
ATE228118T1 (de) * 1999-01-29 2002-12-15 Hoffmann La Roche Reinigung von lipstatin
HK1046092A1 (zh) * 1999-07-14 2002-12-27 Genzyme Corporation 可與脂解酶抑制劑任意配合的脂肪結合聚合物
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
JP2003528830A (ja) 2000-03-10 2003-09-30 ファルマシア・コーポレーション テトラヒドロベンゾチエピン類の製造方法
EP1142572A1 (de) * 2000-04-04 2001-10-10 Volker Dr. Helmstädter Oxetanon-enthaltende Präparate zur Behandlung von Darmerkrankungen
DE10021618A1 (de) * 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
ATE334662T1 (de) * 2000-06-27 2006-08-15 Hoffmann La Roche Herstellungsverfahren von arzneizubereitungen
SI1307264T1 (en) * 2000-07-28 2005-02-28 F. Hoffmann-La Roche Ag New pharmaceutical composition
DK1307263T3 (da) * 2000-07-28 2005-08-22 Hoffmann La Roche Hidtil ukendt anvendelse af lipaseinhibitorer
CN1323661C (zh) * 2000-08-09 2007-07-04 霍夫曼-拉罗奇有限公司 脂酶抑制剂的用途
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
AU2002221670B2 (en) 2000-10-16 2006-11-02 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-HT2 receptor ligands
GB0030710D0 (en) * 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
EP1347979B1 (en) 2000-12-27 2007-08-08 F. Hoffmann-La Roche Ag Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
US20030072804A1 (en) * 2001-03-19 2003-04-17 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
US20030091610A1 (en) * 2001-03-19 2003-05-15 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
KR100621287B1 (ko) 2001-05-21 2006-09-13 에프. 호프만-라 로슈 아게 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049345B2 (en) 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
EP1446125B1 (en) * 2001-08-30 2009-04-29 Alizyme Therapeutics Limited Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
GB0125659D0 (en) * 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
WO2003040127A1 (en) 2001-11-02 2003-05-15 G.D. Searle Llc Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
AU2002359601A1 (en) 2001-12-04 2003-06-17 Biogal Gyogyszergyar Rt A fermentation process for lipstatin and method of extracting lipstatin from a fermentation broth
IL162323A0 (en) 2001-12-04 2005-11-20 Biogal Pharmaceutical Co Preparation of orlistat and orlistat crystalline forms
BR0215080A (pt) 2001-12-20 2004-10-05 Osi Pharm Inc Composto inibidores de lipase pancreática, sua sìntese e uso
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
ES2304498T3 (es) * 2002-02-04 2008-10-16 F. Hoffmann-La Roche Ag Derivados de quinolina como antagonistas de npy.
WO2003072577A1 (en) * 2002-02-28 2003-09-04 F.Hoffmann-La Roche Ag Thiazole derivatives as npy receptor antagonists
WO2003088975A1 (en) * 2002-04-17 2003-10-30 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
US7728153B2 (en) 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
ATE453390T1 (de) * 2002-04-26 2010-01-15 Hoffmann La Roche Pharmazeutische zusammensetzung enthaltend einen lipase - inhibitor und glucomannan
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
EP1560816A1 (en) * 2002-07-05 2005-08-10 F. Hoffmann-La Roche Ag Quinazoline derivatives
RU2324685C2 (ru) * 2002-08-07 2008-05-20 Ф.Хоффманн-Ля Рош Аг Производные тиазола, способ их получения и применение, фармацевтическая композиция, обладающая свойствами антагонистов рецепторов npy
PT1539746E (pt) * 2002-09-12 2007-02-28 Hoffmann La Roche Compostos de ácido 1h-indol-5-propiónico, substituído em n, como agonistas de ppar (receptores activados dos proliferadores de peroxissoma), úteis para o tratamento de diabetes
ATE405560T1 (de) * 2002-11-25 2008-09-15 Hoffmann La Roche Indolderivaten
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040178058A1 (en) * 2003-03-10 2004-09-16 Hsueh-Chung Chen Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
EP1658283A2 (en) * 2003-05-30 2006-05-24 Ranbaxy Laboratories, Ltd. Substituted pyrrole derivatives and their use as hmg-co inhibitors
WO2004113314A1 (en) * 2003-06-23 2004-12-29 Biocon Limited Novel boronate esters
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
AU2003253254A1 (en) * 2003-07-17 2005-02-04 Biocon Limited Preparation of tetrahydrolipstatin by hydrogenation of lipstatin, solvent extraction and purification
RU2321586C2 (ru) * 2003-08-12 2008-04-10 Ф.Хоффманн-Ля Рош Аг Производные тиазола в качестве антагонистов npy
EP1658288B1 (en) * 2003-08-12 2007-12-05 F. Hoffmann-La Roche Ag 2-amino-5-benzoylthiazole npy antagonists
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
US7547693B2 (en) 2003-09-22 2009-06-16 Banyu Pharmaceutical Co. Ltd. Piperidine derivative
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
BRPI0416639A (pt) 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050171027A1 (en) * 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
PL209905B1 (pl) * 2004-01-15 2011-11-30 Bringwell Internat Ab Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
KR20060124679A (ko) 2004-01-16 2006-12-05 후지 세이유 가부시키가이샤 리파아제 저해제
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
EP3263118B1 (en) 2004-05-10 2019-09-25 University of Copenhagen Flaxseeds for body weight management
US7879866B2 (en) * 2004-07-19 2011-02-01 Dorte Xenia Gram Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
AU2006243243B2 (en) * 2005-05-03 2009-05-14 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-HT2 ligands
JP5154927B2 (ja) 2005-05-30 2013-02-27 Ｍｓｄ株式会社 新規ピペリジン誘導体
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007018248A1 (ja) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. ピリドン化合物
CA2618568A1 (en) * 2005-08-18 2007-02-22 F. Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as h3 receptor modulators
DE602006017712D1 (de) 2005-08-24 2010-12-02 Banyu Pharma Co Ltd Phenylpyridonderivat
CA2621470A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
US7355055B2 (en) * 2005-09-08 2008-04-08 Reliance Life Sciences Pvt. Ltd. Compounds for treatment of lipase-mediated diseases
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
KR20080059233A (ko) 2005-10-21 2008-06-26 노파르티스 아게 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
AU2006312557B2 (en) 2005-11-10 2011-12-08 Msd K.K. Aza-substituted spiro derivative
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP1968967B1 (en) * 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators
ES2359739T3 (es) * 2005-11-30 2011-05-26 F. Hoffmann-La Roche Ag Derivados de indol-2-il-amida 1,5-sustituida.
AU2006319235A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
JP2009518351A (ja) * 2005-12-09 2009-05-07 エフ．ホフマン−ラ ロシュ アーゲー 肥満症の処置に有用な三環性アミド誘導体
ATE449776T1 (de) * 2005-12-15 2009-12-15 Hoffmann La Roche Pyrroloä2,3-cüpyridinderivate
JP2009519293A (ja) * 2005-12-16 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー Ｈ３レセプター調節剤としてのピロロ［２，３−ｂ］ピリジン誘導体
SK22006A3 (sk) * 2006-01-03 2007-08-02 Biotika, A. S. Kmeň Streptomyces toxytricini produkujúci lipstatín a príprava lipstatínu s uvedeným kmeňom
US20080021092A1 (en) * 2006-01-06 2008-01-24 Deepak Murpani Stable pharmaceutical compositions of orlistat
CA2635719A1 (en) * 2006-01-13 2007-07-19 F. Hoffmann-La Roche Ag Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators
DE602007008831D1 (de) * 2006-01-23 2010-10-14 Hoffmann La Roche Cyclohexyl-sulfonamid-derivate mit h3-rezeptoraktivität
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US7432255B2 (en) * 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
JP2009538859A (ja) * 2006-05-30 2009-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペリジニルピリミジン誘導体
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
AR063275A1 (es) * 2006-10-12 2009-01-14 Epix Delaware Inc Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
AP2009005026A0 (en) * 2007-04-09 2009-12-31 Scidose Llc Combinations of statins and anti-obesity agent
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
EP2166843A4 (en) 2007-06-01 2010-08-11 Univ Princeton TREATMENT OF VIRUS INFECTIONS BY MODULATION OF HOST CELL METABOLISMS
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR101504777B1 (ko) * 2007-06-06 2015-03-20 랜박시 래보러터리스 리미티드 오르리스타트의 제조 방법
EP2190303A1 (en) * 2007-09-12 2010-06-02 Københavns Universitet Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
BRPI0817053A2 (pt) * 2007-09-17 2015-03-24 Reddys Lab Ltd Dr Formulações farmacêuticas de orlistat
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
EP2219614A1 (en) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmaceutical composition of orlistat
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
WO2009076512A1 (en) 2007-12-11 2009-06-18 Epix Delaware, Inc. Carboxamidξ compounds and their use as chemokine receptor agonists
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
WO2009110510A1 (ja) 2008-03-06 2009-09-11 萬有製薬株式会社 アルキルアミノピリジン誘導体
EP2268822B1 (en) 2008-03-26 2019-08-28 Biocon Limited Improved fermentation process for higher yield coefficient of lipase-inhibitor with respect to consumed fatty acid
CA2717384A1 (en) 2008-03-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
EP2141236A1 (en) * 2008-07-03 2010-01-06 KRKA, D.D., Novo Mesto Process for production of lipstatin and microorganisms therefore
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JPWO2010013595A1 (ja) 2008-07-30 2012-01-12 Ｍｓｄ株式会社 ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体
WO2010039019A1 (es) 2008-10-03 2010-04-08 Sigma Alimentos, S.A. De C.V. Composición para promover el control de colesterol total y ldl y/o la pérdida de peso y/o la termogénesis
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
WO2010043592A1 (en) * 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100215635A1 (en) * 2009-02-23 2010-08-26 Zoltan Kiss Small molecules to induce weight loss or to reduce weight gain
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
RU2412713C2 (ru) * 2009-05-14 2011-02-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Фармацевтическая композиция, биологически активная добавка и способ уменьшения поглощения жира из пищи
WO2011028309A1 (en) 2009-09-04 2011-03-10 University Of Toledo PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY
ES2527179T3 (es) 2009-11-02 2015-01-21 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
US8524909B2 (en) 2010-02-02 2013-09-03 Hoffmann-La Roche Inc. Tetrahydro-pyran derivatives
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
WO2011149416A1 (en) 2010-05-24 2011-12-01 Swedish Oat Fiber Ab Aqueous dispersion comprising galactolipids and method for production thereof
EP2392327A1 (en) 2010-06-04 2011-12-07 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Use of orlistat for the anti-parasitic treatment of a parasitic disease
CA2802832A1 (en) 2010-07-06 2012-01-12 Astrazeneca Ab Therapeutic agents 976
CN101885713B (zh) * 2010-07-19 2011-11-30 大邦(湖南)生物制药有限公司 一种毒三素链霉菌发酵液中分离提取利普司他汀的工艺
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN101948450B (zh) * 2010-10-13 2013-04-24 鲁南制药集团股份有限公司 一种生产制备奥利司他的方法
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
PL3400944T3 (pl) 2010-11-04 2020-11-16 Albireo Ab Inhibitory ibat w leczeniu chorób wątroby
CN105287604B (zh) 2010-11-08 2019-07-09 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2680874A2 (en) 2011-03-04 2014-01-08 Pfizer Inc Edn3-like peptides and uses thereof
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN102304105B (zh) * 2011-07-15 2013-07-10 鲁南新时代生物技术有限公司 一种制备高纯度奥利司他的方法
CN103030613B (zh) * 2011-09-29 2014-11-12 北大方正集团有限公司 一种利普司他汀的提纯方法
JP2013249293A (ja) * 2012-06-04 2013-12-12 Kao Corp リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
BR112015002080A2 (pt) 2012-08-02 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
WO2014060445A1 (en) 2012-10-19 2014-04-24 Akzo Nobel Chemicals International B.V. Method for preparing high purity orlistat
CN102936234B (zh) * 2012-11-15 2015-04-01 江苏阿尔法药业有限公司 一种制备脂肪酶抑制剂奥利司他的方法
CN102993134B (zh) * 2012-12-31 2015-08-05 鲁南新时代生物技术有限公司 一种利普司他汀的提纯方法
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2909442A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
KR20230137362A (ko) 2016-05-05 2023-10-04 어퀘스티브 테라퓨틱스, 아이엔씨. 강화된 전달 에프네프린 조성물
US20180134667A1 (en) 2016-10-14 2018-05-17 TES Pharma S.r.I. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
SG11202104550WA (en) 2018-11-20 2021-05-28 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
KR20210116548A (ko) 2019-01-18 2021-09-27 아스트라제네카 아베 Pcsk9 억제제 및 이의 이용 방법
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
US20230338387A1 (en) 2020-02-05 2023-10-26 Nof Corporation Agent For Treating Or Preventing Pancreatic Fistula

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
GB2023604B (en) * 1978-05-25 1982-07-28 Microbial Chem Res Found Physiologically active derivatives of esterastin and production thereof
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones

Also Published As

Publication number Publication date
NO159941C (no) 1989-02-22
DK160496B (da) 1991-03-18
PT78777B (en) 1986-09-15
HUT34545A (en) 1985-03-28
FI78694C (fi) 1989-09-11
MC1602A1 (fr) 1985-05-09
EP0129748A1 (de) 1985-01-02
AU2947884A (en) 1985-01-03
EP0129748B1 (de) 1987-09-30
MX9203633A (es) 1992-07-01
IL72122A (en) 1987-07-31
KR920002314B1 (ko) 1992-03-21
KR850000530A (ko) 1985-02-27
PH19704A (en) 1986-06-16
NO159941B (no) 1988-11-14
IE841566L (en) 1984-12-22
NL980029I1 (nl) 1999-01-04
DE19875045I2 (de) 2000-01-20
GR82120B (instruction) 1984-12-13
FI842422A0 (fi) 1984-06-14
IL72122A0 (en) 1984-10-31
IE57761B1 (en) 1993-03-24
NO842512L (no) 1984-12-27
LV5747B4 (lv) 1996-12-20
ES8600650A1 (es) 1985-10-16
ATE30025T1 (de) 1987-10-15
JPH0516426B2 (instruction) 1993-03-04
PT78777A (en) 1984-07-01
NL980029I2 (nl) 1999-06-01
NO2000003I1 (no) 2000-05-31
NZ208521A (en) 1988-02-29
CA1247547A (en) 1988-12-28
HU193579B (en) 1987-10-28
DK308584A (da) 1984-12-23
AU572851B2 (en) 1988-05-19
JPS6013777A (ja) 1985-01-24
LU90302I2 (fr) 1998-12-21
LV5747A4 (lv) 1996-10-20
FI842422L (fi) 1984-12-23
ZA844558B (en) 1985-02-27
DK308584D0 (da) 1984-06-22
ES533557A0 (es) 1985-10-16
DK160496C (da) 1991-08-26
FI78694B (fi) 1989-05-31
US4598089A (en) 1986-07-01
DE3466538D1 (de) 1987-11-05

Similar Documents

Publication Publication Date Title
BG60766B2 (bg) Производни на хексадеканова и хексадекадиенова киселини
JPH03197492A (ja) Ｂｕ―４０６１ｔ
KR100366258B1 (ko) 신규 kf-1040 물질 및 그 제조법
FR2478096A1 (fr) Lactones physiologiquement actives presentant des proprietes immunopotentialisatrices et anti-inflammatoires, leur procede de production et les compositions pharmaceutiques les renfermant
NL8501708A (nl) Antitumor antibioticum.
KR100446323B1 (ko) Ｇｍ-95 물질, 이의 제조 방법 및 용도
JPH0447648B2 (instruction)
US3812249A (en) Antibiotic bl580
AU2002250997B2 (en) Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of CNS disorders and a process for the preparation thereof
CN1045997C (zh) 抗球虫剂组合物及其制备方法
DE3889213T2 (de) Antibiotika NK 86-0279, deren Verfahren zur Herstellung und deren Benutzung.
EP0525361B1 (en) Novel antibiotics NK374186A, NK374186B, NK374186B3 and NK374186C3, process for producing the same, and use of the same
JP3124373B2 (ja) 免疫抑制物質
CA2017276C (en) Carcinostatic or antitumor antibiotic, conagenin, and production and uses thereof
JP3034646B2 (ja) Ｇ−ｃｓｆおよびｇｍ−ｃｓｆ誘導剤
JP2799581B2 (ja) 化合物ｔａｎ―１１４０およびその製造法
JPH05213758A (ja) 血小板増多剤
JPH05221867A (ja) Ｉｌ−６誘導剤
JPH0479354B2 (instruction)
EP0314401A2 (en) New compound WF 2015 A and B, production thereof and use thereof
JPH0631283B2 (ja) 生理活性物質ｆａ−１８１９，その製造法およびそれを含有する治療剤
EP0451273A1 (en) Polyether antibiotic mi215-nf3, production thereof, and drug for treating fowl coccidiosis
JPH10265491A (ja) 新規テルペン系化合物０４０６ｔｐ−１
JP2002068980A (ja) 生理活性物質ｎｋ３４８９６類縁体の用途
JP2002069075A (ja) 新規生理活性物質ｎｋ３４８９６ｂ、及びその製造法